Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock Price Down 3.4%
Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock Price Down 3.4%
Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) shares dropped 3.4% during mid-day trading on Thursday . The company traded as low as $1.66 and last traded at $1.73. Approximately 24,926 shares changed hands during trading, a decline of 70% from the average daily volume of 82,503 shares. The stock had previously closed at $1.79.
Can-Fite BioPharma Ltd.（紐約證券交易所美國證券交易所代碼：CANF — 獲取評級）股價在週四午盤交易中下跌了3.4％。該公司的交易價格低至1.66美元，最後一次交易價格爲1.73美元。交易期間約有24,926股易手，較平均每日交易量82,503股下降了70％。該股此前收於1.79美元。
Analyst Ratings Changes
分析師評級變化
Several research firms have recently weighed in on CANF. StockNews.com upgraded Can-Fite BioPharma from a "sell" rating to a "hold" rating in a report on Saturday, April 1st. Dawson James cut Can-Fite BioPharma from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Can-Fite BioPharma in a research note on Monday, March 13th.
幾家研究公司最近對CANF進行了權衡。StockNews.com在4月1日星期六的一份報告中將Can-Fite BioPharma的評級從 “賣出” 上調至 “持有” 評級。道森·詹姆斯在1月3日星期二的一份研究報告中將Can-Fite BioPharma的評級從 “買入” 下調至 “中性” 評級。最後，HC Wainwright在3月13日星期一的一份研究報告中重申了 “買入” 評級，並對Can-Fite BioPharma的股票發佈了34.00美元的目標股價。
Can-Fite BioPharma Price Performance
Can-Fite BioPharma 的價格表現
The firm has a 50 day moving average of $2.70 and a two-hundred day moving average of $1.97.
該公司的50天移動平均線爲2.70美元，200天移動平均線爲1.97美元。
Institutional Investors Weigh In On Can-Fite BioPharma
機構投資者正在關注 Can-Fite BioPharma
A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Virtu Financial LLC acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) during the second quarter, according to its most recent filing with the SEC. The fund acquired 56,322 shares of the biotechnology company's stock, valued at approximately $52,000. Virtu Financial LLC owned 0.21% of Can-Fite BioPharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.82% of the company's stock.
一家對沖基金最近購買了Can-Fite BioPharma股票的新股份。根據向美國證券交易委員會提交的最新文件，Virtu Financial LLC在第二季度收購了Can-Fite BioPharma Ltd.（紐約證券交易所美國證券交易所代碼：CANF — 獲取評級）的新股份。該基金收購了這家生物技術公司的56,322股股票，價值約52,000美元。截至最近向美國證券交易委員會提交文件，Virtu Financial LLC擁有Can-Fite BioPharma0.21％的股份。機構投資者和對沖基金擁有該公司1.82％的股票。
Can-Fite BioPharma Company Profile
Can-Fite BioPharma 公司簡介
(Get Rating)
（獲取評分）
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Can-Fite BioPharma Ltd.是一家生物製藥公司，從事治療癌症、肝臟和炎症性疾病以及勃起功能障礙的藥物的開發。其產品線包括 Piclidenoson、Namodenoson 和 CF602。該公司由Pnina Fishman和Ilan Cohn於1994年9月11日創立，總部位於以色列的Petach-Tikva。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on Can-Fite BioPharma (CANF)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- 免費獲取 StockNews.com 關於 Can-Fite BioPharma（CANF）的研究報告的副本
- MarketBeat 週迴顧 — 4 月 17 日 — 4 月 21 日
- 2 只工業實力股息股票正在融化
- 寶潔將創下新高
- AutoNation的計劃讓分析師待在身邊
- Netflix 增加回購：它能否在 2023 年完成逆轉？
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Can-Fite BioPharma Daily 的新聞和評級 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Can-Fite BioPharma及相關公司的最新新聞和分析師評級的簡明每日摘要。